Nivolumab (Opdivo)

General information

Class/mechanism: PD-1 receptor antibody. Nivolumab is an IgG4 kappa human monoclonal antibody which binds to the PD-1 (programmed death receptor-1) receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Normally, PD-L1 and PD-L2 binding to the PD-1 receptor on T cells inhibits T-cell proliferation and cytokine production, which can impede immune system surveillance of tumors. By interfering with the binding of PD-L1 and PD-L2 to the PD-1 receptor, nivolumab can cause upregulation of the anti-tumor immune response.
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Toxicity management

• Immunotherapy toxicity management

Diseases for which it is established (work in progress)

• Bladder cancer
• Esophageal cancer
  • Esophageal adenocarcinoma
  • Esophageal squamous cell carcinoma
• Gastric cancer
• Head and neck cancer
• Hepatocellular carcinoma
• Malignant pleural mesothelioma
• Melanoma
  • Uveal melanoma
• Non-small cell lung cancer
  • Non-small cell lung cancer, nonsquamous
  • Non-small cell lung cancer, squamous
• Renal cell carcinoma
  • Clear cell renal cell carcinoma

Diseases for which it is used

• Anal cancer
• Cholangiocarcinoma
• Colorectal cancer
• Hodgkin lymphoma

Diseases for which it was used

• Small cell lung cancer

Patient drug information

• Nivolumab (Opdivo) package insert
• Nivolumab (Opdivo) patient drug information (Chemocare)
• Nivolumab (Opdivo) patient drug information (UpToDate)

History of changes in FDA indication

Bladder cancer

• 2/2/2017: Granted accelerated approval for treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing chemotherapy. (New disease entity; based on CheckMate 275)
• 8/19/2021: Approved for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection. (Extended to adjuvant setting; converted to regular approval; based on CheckMate 274)

Colorectal cancer

• 8/1/2017: Granted FDA accelerated approval for the treatment of patients 12 years and older with mismatch repair deficient (dMMR) and microsatellite instability high (MSI-H) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Based on CheckMate 142)
• 7/10/2018: Accelerated approval for treatment of adult and pediatric patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with ipilimumab. (Based on CheckMate 142)

Esophageal cancer

• 6/10/2020: for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (New disease entity; based on ATTRACTION-3)
• 4/16/2021: Approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. (Based on CheckMate 649)
• 5/20/2021: Approved for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy. (Based on CheckMate 577)
• 5/27/2022: Approved for the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) in combination with fluoropyrimidine- and platinum-based chemotherapy. (Based on CheckMate 648)
• 5/27/2022: Approved for the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) in combination with ipilimumab. (Based on CheckMate 648)

Gastric cancer

• 4/16/2021: Approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. (Based on CheckMate 649)

Head and neck cancer

• 11/10/2016: FDA approved for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy. (New disease entity; based on CheckMate 141)

Hepatocellular carcinoma - PARTIALLY WITHDRAWN

• 9/22/2017: Granted FDA accelerated approval for the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib. (New disease entity; based on CheckMate 040)
  • 7/23/2021: Approval withdrawn.
• 3/10/2020: Accelerated approval in combination with ipilimumab for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. (Approval extended to combination therapy; based on CheckMate 040)

Hodgkin lymphoma

• 5/17/2016: Accelerated approval for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin (Adcetris). (New disease entity; based on CheckMate 039 and CheckMate 205)

Malignant pleural mesothelioma

• 10/2/2020: Approved in combination with ipilimumab as first-line treatment for adult patients with unresectable malignant pleural mesothelioma. (New disease entity; based on CheckMate 743)

Melanoma

• 12/22/2014: Accelerated approval for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab (Based on CheckMate 037)
  • If BRAF V600 mutation positive, a BRAF inhibitor.
  • 3/7/2019: Converted to regular approval.
• 9/30/2015: Granted accelerated approval in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma. (Based on CheckMate 066 and CheckMate 067)
• 9/13/2016: FDA dosing recommendation changed to 240 mg IV every two weeks until disease progression or intolerable toxicity for renal cell carcinoma, metastatic melanoma, and non-small cell lung cancer. When combined with ipilimumab for melanoma, after completion of ipilimumab, the recommended nivolumab dose will be 240 mg every two weeks until disease progression or intolerable toxicity.
• 12/20/2017: Granted regular approval for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection. (Based on CheckMate 238)

Non-small cell lung cancer

• 3/4/2015: Approved for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. (New disease entity; based on CheckMate 017)
• 10/9/2015: Approval expanded for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. (Histology indication expanded to include nonsquamous; based on CheckMate 057)
  • Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Opdivo.
• 9/13/2016: FDA dosing recommendation changed to 240 mg IV every two weeks until disease progression or intolerable toxicity for renal cell carcinoma, metastatic melanoma, and non-small cell lung cancer. When combined with ipilimumab for melanoma, after completion of ipilimumab, the recommended nivolumab dose will be 240 mg every two weeks until disease progression or intolerable toxicity.
• 5/15/2020: Approved in combination with ipilimumab as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (≥1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. (Expanded to first-line setting, with PD-L1 expression requirement; based on CheckMate 227)
• 5/26/2020: Approved in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. (PD-L1 expression requirement removed when given with chemotherapy; based on CheckMate 9LA)
• 3/4/2022: Approved with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting. (Based on CheckMate 816)

Renal cell carcinoma

• 11/23/2015: FDA approval expanded for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. (New disease entity; based on CheckMate 025)
• 9/13/2016: FDA dosing recommendation changed to 240 mg IV every two weeks until disease progression or intolerable toxicity for renal cell carcinoma, metastatic melanoma, and non-small cell lung cancer. When combined with ipilimumab for melanoma, after completion of ipilimumab, the recommended nivolumab dose will be 240 mg every two weeks until disease progression or intolerable toxicity.
• 4/16/2018: FDA approved to be used in combination with Ipilimumab (Yervoy) for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. (Based on CheckMate 214)
• 1/22/2021: Approved to be used in combination with Cabozantinib (Cabometyx) as first-line treatment for patients with advanced renal cell carcinoma (RCC). (Based on CheckMate 9ER)

Small cell lung cancer - WITHDRAWN

• 8/16/2018: Granted FDA accelerated approval for patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. (Based on CheckMate 032)
  • 12/29/2020: Approval withdrawn.

History of changes in EMA indication

• 6/19/2015: Initial marketing authorization as Opdivo.

Also known as

• Code names: BMS-936558, MDX-1106, ONO-4538
• Brand name: Opdivo